• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Ex-Advanced BioHealing exec draws probation in VA fraud case

February 12, 2018 By Brad Perriello

Advanced BioHealingA former Advanced BioHealing executive who admitted to federal charges that he bribed U.S. Veterans Affairs Dept. doctors to use the company’s DermaGraft biologic wound dressing last week drew probation in the case.

Federal had prosecutors accused Todd Clawson, who left the company in 2012, of participating in a scheme to bribe VA physicians to use the DermaGraft diabetic foot ulcer treatment with a series of inducements including paid trips to Cabo San Lucas, Mexico, Def Leppard concert tickets, a fishing trip in Wyoming and junkets to Las Vegas with an ocean fishing kayak, according to court documents. Clawson pleaded guilty in March 2016 to a single count of conspiracy to commit criminal conflicts of interest, bribery and healthcare fraud.

Judge Robert Lasnik of the U.S. District Court for Western Washington sentenced Clawson Feb. 9 to a three-year probation term and ordered him to pay a $5,000 fine, according to court documents.

“I am sick over my actions,” Clawson told Lasnik,  according to the Seattle Post-Intelligencer, adding that Advanced BioHealth would have fired him if he refused to go along with the kickbacks program.

“Greed is an ugly, ugly emotion,” Clawson said, the newspaper reported.

Shire (NSDQ:SHPGY), which paid $750 million for Advanced BioHealing in June 2011, abandoned its pursuit of a venous leg ulcer indication for DermaGraft after a Phase III clinical trial failed to meet its primary endpoint.

A patent infringement lawsuit and a U.S. Justice Dept. probe followed, and by 2014, the Irish pharma giant had lost patience, dealing the company to erstwhile rival Organogenesis, for just $300 million. And early this year Shire agreed to cough up $350 million to settle the DoJ probe.

Filed Under: Featured, Legal News, Regenerative Medicine, Wound Care Tagged With: Advanced BioHealing, Shire

IN CASE YOU MISSED IT

  • Medtronic moves to divest final stake in MiniMed
  • Dexcom adds former Stryker CFO to board
  • MiniMed wins CE mark for next-gen insulin pump, ups revenue guidance
  • Abbott wins FDA authorization for dual glucose-ketone sensor
  • FDA clears Roche’s Alzheimer’s blood test for rule-in and rule-out assessment 

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS